ArticleJournal of translational medicine2026
Shikonin triggers apoptosis in lung adenocarcinoma through the FHL2-FOXO1 signaling axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFHL2 is an oncogenic scaffold protein that is overexpressed in lung adenocarcinoma (LUAD), making it a promising therapeutic target. SHK, a natural naphthoquinone, exhibits antitumor activity, but its molecular mechanism in LUAD, particularly its relationship with FHL2, remains unclear. AIM OF THIS STUDY: The present study aimed to define the effects of SHK on NSCLC and identify the potential underlying molecular mechanisms.
methodsThe anti-tumor effects of SHK were evaluated in LUAD cell lines (A549andH1299) and a patient-derived xenograft (PDX) model using CCK-8, colony formation, Transwell, and flow cytometry assays. Integrated proteomics, bioinformatics, molecular docking, and cellular thermal shift assays (CETSAs) were employed to identify the direct target of SHK. The underlying mechanism was investigated through co-immunoprecipitation (Co-IP), Western blotting, qRT-PCR, cycloheximide (CHX) chase assays, and immunofluorescence/immunohistochemiscal (IF/IHC) staining.
resultsIn both in vitro and PDX models, SHK potently inhibited LUAD growthand metastasisand induced cell death. At the molecular level, FHL2 was identified as a direct target of SHK. The direct binding of SHK to FHL2 promoted its proteasomal degradation, thereby disrupting the FHL2-FOXO1 complex. The dissociation of this complex increased FOXO1 acetylation and promoted its nuclear translocation, leading to the subsequent activation of the caspase cascade and apoptosis.
conclusionOur findings indicate a novel signaling pathway through which SHK inhibits LUAD: by directly targeting FHL2 for degradation, SHK disrupts the FHL2-FOXO1 complex, which activates FOXO1-mediated transcription and triggers apoptosis. This study not only provides mechanistic insight into the antitumor function of SHK but also identifies the FHL2-FOXO1 axis as a potential therapeutic target for LUAD.
Indexed as
Identifiers
42919378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.